Change in Management by way of appointment of Additional Directors and Internal Auditor.

Oxygenta Pharmaceutical Ltd held a board meeting on May 23, 2026, approving audited financial results and making key appointments. The company posted total revenue of Rs 11,326.77 lakhs for FY2025-26 (vs Rs 11,060.77 lakhs previous year), but losses nearly doubled — net loss of Rs 1,757.17 lakhs compared to Rs 1,029.83 lakhs last year. The company remains a subsidiary of Virupaksha Organics Limited after the latter acquired a 56.5% stake in June 2025. Two Additional Directors were appointed: Mr. Amireddy Venkatesu Reddy (Executive, 3-year term) and Mr. Janardhana Reddy Yeddula (Independent, 5-year term), both subject to shareholder approval. Mr. Janardhana Reddy is also an Independent Director at the holding company Virupaksha Organics. M/s. Suryachandra & Associates was appointed as Internal Auditors for FY 2026-27. The company flagged ongoing challenges identifying MSME creditors and managing trade receivables with an Expected Credit Loss provision of Rs 52.86 lakhs.